Leerink Partnrs Research Analysts Lower Earnings Estimates for Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL)

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) – Analysts at Leerink Partnrs dropped their FY2026 earnings estimates for Zentalis Pharmaceuticals in a report released on Wednesday, June 19th. Leerink Partnrs analyst A. Berens now anticipates that the company will earn ($3.83) per share for the year, down from their prior forecast of ($3.74). The consensus estimate for Zentalis Pharmaceuticals’ current full-year earnings is ($2.72) per share.

ZNTL has been the topic of several other research reports. HC Wainwright dropped their price target on shares of Zentalis Pharmaceuticals from $40.00 to $20.00 and set a “buy” rating on the stock in a research report on Tuesday, June 18th. Stifel Nicolaus dropped their price target on shares of Zentalis Pharmaceuticals from $32.00 to $10.00 and set a “buy” rating on the stock in a research report on Tuesday, June 18th. Oppenheimer dropped their price target on shares of Zentalis Pharmaceuticals from $50.00 to $25.00 and set an “outperform” rating on the stock in a research report on Tuesday, June 18th. Wells Fargo & Company lowered shares of Zentalis Pharmaceuticals from an “overweight” rating to an “equal weight” rating and dropped their price target for the company from $29.00 to $9.00 in a research report on Tuesday, June 18th. Finally, UBS Group downgraded shares of Zentalis Pharmaceuticals from a “buy” rating to a “neutral” rating and decreased their price objective for the company from $28.00 to $5.00 in a report on Thursday, June 20th. One research analyst has rated the stock with a sell rating, six have assigned a hold rating and three have given a buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $11.33.

Zentalis Pharmaceuticals Stock Performance

ZNTL stock opened at $4.20 on Monday. The firm has a market cap of $298.33 million, a PE ratio of -1.26 and a beta of 1.83. The firm’s fifty day moving average is $10.64 and its 200 day moving average is $12.82. Zentalis Pharmaceuticals has a one year low of $3.93 and a one year high of $29.42.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last released its quarterly earnings results on Tuesday, May 7th. The company reported $0.14 EPS for the quarter, beating the consensus estimate of ($0.77) by $0.91. The firm had revenue of $40.56 million for the quarter, compared to analyst estimates of $35.00 million. During the same quarter in the prior year, the business posted ($1.07) EPS.

Hedge Funds Weigh In On Zentalis Pharmaceuticals

A number of institutional investors have recently bought and sold shares of the company. Eventide Asset Management LLC raised its stake in Zentalis Pharmaceuticals by 47.9% during the fourth quarter. Eventide Asset Management LLC now owns 11,559,975 shares of the company’s stock worth $175,134,000 after purchasing an additional 3,745,936 shares during the period. Vanguard Group Inc. raised its stake in Zentalis Pharmaceuticals by 6.2% during the third quarter. Vanguard Group Inc. now owns 5,236,663 shares of the company’s stock worth $105,047,000 after purchasing an additional 307,490 shares during the period. Price T Rowe Associates Inc. MD raised its stake in Zentalis Pharmaceuticals by 20.2% during the first quarter. Price T Rowe Associates Inc. MD now owns 3,489,709 shares of the company’s stock worth $54,999,000 after purchasing an additional 585,644 shares during the period. Federated Hermes Inc. increased its position in shares of Zentalis Pharmaceuticals by 10.9% during the fourth quarter. Federated Hermes Inc. now owns 2,160,565 shares of the company’s stock valued at $32,733,000 after acquiring an additional 212,872 shares during the last quarter. Finally, Decheng Capital LLC acquired a new stake in shares of Zentalis Pharmaceuticals during the fourth quarter valued at about $31,809,000.

Insider Transactions at Zentalis Pharmaceuticals

In other news, CFO Cam Gallagher sold 9,597 shares of the firm’s stock in a transaction dated Friday, May 31st. The shares were sold at an average price of $11.98, for a total value of $114,972.06. Following the transaction, the chief financial officer now directly owns 633,680 shares of the company’s stock, valued at $7,591,486.40. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. In other news, insider Diana Hausman sold 3,356 shares of the firm’s stock in a transaction dated Thursday, May 9th. The shares were sold at an average price of $12.62, for a total value of $42,352.72. Following the transaction, the insider now directly owns 373,876 shares of the company’s stock, valued at $4,718,315.12. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CFO Cam Gallagher sold 9,597 shares of Zentalis Pharmaceuticals stock in a transaction dated Friday, May 31st. The stock was sold at an average price of $11.98, for a total transaction of $114,972.06. Following the transaction, the chief financial officer now directly owns 633,680 shares in the company, valued at $7,591,486.40. The disclosure for this sale can be found here. Insiders own 6.10% of the company’s stock.

About Zentalis Pharmaceuticals

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.